Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?

NCT04517175 is registered in ClinicalTrials.gov with Maastricht University as lead sponsor.

NCT NCT04517175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
Lead sponsor
Maastricht University
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2020
Completion date
September 1, 2025
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome/neoplasm, myelodysplastic syndromes